Literature DB >> 11377301

Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey.

J N Liberman1, T L Hunt, W F Stewart, A Wein, Z Zhou, A R Herzog, R B Lipton, A C Diokno.   

Abstract

OBJECTIVES: To assess, by means of a survey, the impact of the symptoms of overactive bladder (urinary frequency, urgency, and urge incontinence) on the quality of life in a community-based sample of the U.S. population.
METHODS: A telephone survey was conducted in the United States among an age and sex-stratified sample of 4896 noninstitutionalized adults 18 years of age and older. From the responses to the telephone survey, a total of 483 individuals with symptoms of overactive bladder and 191 controls completed a mailed follow-up questionnaire to assess their quality of life using the Medical Outcomes Study Short-Form 20.
RESULTS: After adjustment for age, sex, and the use of medical care, the greatest differences in the quality-of-life scores between the patients with incontinent overactive bladders and the controls were in the health perception (17.6 points; P <0.001) and role functioning (13.0 points; P <0.001) scales. Those with an overactive bladder with the symptoms of frequency or urgency, or both, but without incontinence, also had significantly lower scores than did the controls in mental health (P = 0.026), health perception (P = 0.01), and bodily pain (P = 0.016).
CONCLUSIONS: These data indicate that individuals with an overactive bladder experience decrements in their quality of life relative to community controls. An important new finding from this study is that individuals with an overactive bladder, even without demonstrable urine loss, also have a poorer quality of life than that of controls.

Entities:  

Mesh:

Year:  2001        PMID: 11377301     DOI: 10.1016/s0090-4295(01)00986-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  49 in total

1.  [Urinary incontinence in old age--state of the art].

Authors:  I Füsgen
Journal:  Z Gerontol Geriatr       Date:  2005-09       Impact factor: 1.281

2.  Effect of desmopressin with anticholinergics in female patients with overactive bladder.

Authors:  Young Kook Han; Won Ki Lee; Seong Ho Lee; Dae Yul Yang; Hayoung Kim
Journal:  Korean J Urol       Date:  2011-06-17

3.  Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.

Authors:  Rodney U Anderson; Scott MacDiarmid; Sherron Kell; James H Barada; Scott Serels; Roger P Goldberg
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-05-03

Review 4.  The puzzle of overactive bladder: controversies, inconsistencies, and insights.

Authors:  Roger R Dmochowski
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-06-27

Review 5.  Overactive bladder in the elderly: a guide to pharmacological management.

Authors:  David R Staskin
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 6.  Review of Economic Value Drivers of the Treatment of Overactive Bladder.

Authors:  Sonya J Snedecor
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

Review 7.  Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

Authors:  Hashim Hashim; Paul Abrams
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

Authors:  K Coyne; D Revicki; T Hunt; R Corey; W Stewart; J Bentkover; H Kurth; P Abrams
Journal:  Qual Life Res       Date:  2002-09       Impact factor: 4.147

Review 9.  Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence.

Authors:  J F Wyman; K L Burgio; D K Newman
Journal:  Int J Clin Pract       Date:  2009-07-02       Impact factor: 2.503

10.  Tolterodine extended release is well tolerated in older subjects.

Authors:  T L Griebling; S R Kraus; H E Richter; D B Glasser; M Carlsson
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.